KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

LifeMD (LFMD) Net Income towards Common Stockholders (2016 - 2025)

LifeMD (LFMD) has disclosed Net Income towards Common Stockholders for 14 consecutive years, with -$4.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Income towards Common Stockholders fell 27.3% year-over-year to -$4.9 million, compared with a TTM value of -$13.3 million through Dec 2025, up 45.59%, and an annual FY2025 reading of -$13.3 million, up 45.59% over the prior year.
  • Net Income towards Common Stockholders was -$4.9 million for Q4 2025 at LifeMD, down from -$4.6 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at -$960341.0 in Q1 2025 and bottomed at -$19.0 million in Q4 2021.
  • Average Net Income towards Common Stockholders over 5 years is -$8.6 million, with a median of -$7.5 million recorded in 2023.
  • The sharpest move saw Net Income towards Common Stockholders crashed 398.08% in 2021, then skyrocketed 87.27% in 2025.
  • Year by year, Net Income towards Common Stockholders stood at -$19.0 million in 2021, then skyrocketed by 33.03% to -$12.7 million in 2022, then soared by 64.53% to -$4.5 million in 2023, then grew by 13.86% to -$3.9 million in 2024, then dropped by 27.3% to -$4.9 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for LFMD at -$4.9 million in Q4 2025, -$4.6 million in Q3 2025, and -$2.9 million in Q2 2025.